同和药业：关于获得欧洲药典适应性证书的公告

Core Viewpoint - The company, Tonghua Dongbao Pharmaceutical, has received a revised Certificate of Suitability (CEP) for its Ticagrelor active pharmaceutical ingredient from the European Directorate for the Quality of Medicines (EDQM), effective from September 12, 2025, due to the addition of a new production workshop [1] Group 1 - The revised CEP indicates compliance with European pharmacopoeia standards, which is crucial for market access in Europe [1] - The change in the certificate is a strategic move to enhance production capacity and meet regulatory requirements [1] - The new production facility is expected to support the company's growth in the European market [1]